(Total Views: 583)
Posted On: 02/15/2022 10:14:02 PM
Post# of 153917
Thanks, sean007, but now I wonder how - if we did partner up with a company - for example, for NASH - what's to prevent the Dr from prescribing LL for any number of off-label uses?
For example - if someone has liver disease and LL has been approved to use, then the Dr can prescribe it. But say this Dr has another patient come in with TNBC; can he say he wants to be "proactive" with her liver and prescribe LL - knowing full well the molecule may also stop/reduce her cancer?
My point is, if LL is really the Swiss Army knife of molecules - and since Dr's can prescribe "off label" for other (unapproved) indications - couldn't our potential NASH partner wind up selling LL to any number of patients who, strictly speaking, don't have serious liver issues? In other words, once the door is open to sell LL, when does the door close?
For example - if someone has liver disease and LL has been approved to use, then the Dr can prescribe it. But say this Dr has another patient come in with TNBC; can he say he wants to be "proactive" with her liver and prescribe LL - knowing full well the molecule may also stop/reduce her cancer?
My point is, if LL is really the Swiss Army knife of molecules - and since Dr's can prescribe "off label" for other (unapproved) indications - couldn't our potential NASH partner wind up selling LL to any number of patients who, strictly speaking, don't have serious liver issues? In other words, once the door is open to sell LL, when does the door close?
(2)
(0)
